AR031799A1 - Derivado de [1,2,4]triazolo[1,5-a]piridina - Google Patents

Derivado de [1,2,4]triazolo[1,5-a]piridina

Info

Publication number
AR031799A1
AR031799A1 ARP010105765A ARP010105765A AR031799A1 AR 031799 A1 AR031799 A1 AR 031799A1 AR P010105765 A ARP010105765 A AR P010105765A AR P010105765 A ARP010105765 A AR P010105765A AR 031799 A1 AR031799 A1 AR 031799A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
substituted
dihydro
aryl
halogen
Prior art date
Application number
ARP010105765A
Other languages
English (en)
Inventor
Bernd Brodbeck
Matthias Heinrich Nettekoven
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR031799A1 publication Critical patent/AR031799A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente describe compuestos de la formula general (1), en donde: R1 es alcoxilo inferior, cicloalquilo o arilo, sustituido o no por halogeno o alcoxilo inferior, o es -NR'R'', donde R' y R'' son independientemente uno del otro hidrogeno, alquilo inferior, alquenilo inferior, alquinilo inferior, -(CR2)n-arilo, sustituido o no por uno a tres sustituyentes, seleccionados del grupo, consistente en halogeno o alcoxilo inferior, o son -(CH2)n+1NR2, -(CH2)n-piridinilo, -(CH2)n-indanilo, -(CH2)n-cicloalquilo, -(CH2)n-O-alquilo inferior, -(CH2)n-C(O)-NR2, -(CH2)n-CF3; o R' y R'' son junto al átomo de N al que están unidos pirrolidin-1-ilo, piperidin-1-ilo, 3,4-dihidro-1H-isoquinolin-2-ilo, morfolinilo, azatidin-1-ilo, 3,6-dihidro-2H-piridin-1-ilo, tiomorfolinilo, 2,5-dihidro-pirrol-1-ilo, tiazolidin-3-ilo, piperazinilo, azocan-1-ilo, azepan-1-ilo, octahidroquinolin-1-ilo, octahidroquinolin-2-ilo, 1,3,4,9-tetrahidro-b-carbolin-2-ilo, cuyos anillos pueden estar sustituidos o no por uno a tres sustituyentes, seleccionados del grupo, consistente en alquilo inferior, fenilo, bencilo, piridilo, -C(O)-NR2, -(CH2)n-O-alquilo inferior o -NR-C(O)-alquilo inferior; R2 es arilo o un grupo heteroarilo de 5 o 6 miembros, cuyos anillos están sustituidos o no por alquilo inferior, halogeno, hidroxilo o alcoxilo inferior; X es un enlace o -N(R)CH2-; R es hidrogeno o alquilo inferior; n es 0, 1, 2, 3, 4, 5 o 6; y sus sales farmacéuticamente aceptables. Los compuestos tienen una buena afinidad por el receptor de adenosina y se pueden usar además en el tratamiento de enfermedades relacionadas con este receptor.
ARP010105765A 2000-12-15 2001-12-12 Derivado de [1,2,4]triazolo[1,5-a]piridina AR031799A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00127567 2000-12-15

Publications (1)

Publication Number Publication Date
AR031799A1 true AR031799A1 (es) 2003-10-01

Family

ID=8170683

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105765A AR031799A1 (es) 2000-12-15 2001-12-12 Derivado de [1,2,4]triazolo[1,5-a]piridina

Country Status (21)

Country Link
US (1) US6506772B1 (es)
EP (1) EP1347974B1 (es)
JP (1) JP4049672B2 (es)
KR (1) KR100540628B1 (es)
CN (1) CN1221551C (es)
AR (1) AR031799A1 (es)
AT (1) ATE281456T1 (es)
AU (2) AU3167402A (es)
BR (1) BR0116193A (es)
CA (1) CA2437006C (es)
DE (1) DE60106974T2 (es)
DK (1) DK1347974T3 (es)
ES (1) ES2230387T3 (es)
GT (1) GT200100253A (es)
MX (1) MXPA03005334A (es)
PA (1) PA8534701A1 (es)
PE (1) PE20020666A1 (es)
PT (1) PT1347974E (es)
UY (1) UY27074A1 (es)
WO (1) WO2002048145A1 (es)
ZA (1) ZA200304481B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003277A (es) * 2001-10-08 2004-07-23 Hoffmann La Roche Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico.
JP2006512313A (ja) * 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2008006540A1 (en) * 2006-07-12 2008-01-17 Syngenta Participations Ag Triazolopyridine derivatives as herbicides
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8802696B2 (en) * 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
AU2010247735B2 (en) * 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
WO2013043520A1 (en) * 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
JP7399589B2 (ja) * 2018-09-12 2023-12-18 日本化薬株式会社 有害生物防除剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226735D0 (en) 1992-12-22 1993-02-17 Ici Plc Azole derivatives
US5356894A (en) 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
WO1999043678A1 (fr) 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Medicaments et prophylaxie contre la maladie de parkinson
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives

Also Published As

Publication number Publication date
JP2004521096A (ja) 2004-07-15
BR0116193A (pt) 2003-09-23
GT200100253A (es) 2002-07-31
DE60106974D1 (de) 2004-12-09
JP4049672B2 (ja) 2008-02-20
PT1347974E (pt) 2005-02-28
AU3167402A (en) 2002-06-24
WO2002048145A1 (en) 2002-06-20
KR20030061446A (ko) 2003-07-18
PA8534701A1 (es) 2002-08-26
ATE281456T1 (de) 2004-11-15
PE20020666A1 (es) 2002-07-27
DK1347974T3 (da) 2005-03-14
CA2437006A1 (en) 2002-06-20
CN1221551C (zh) 2005-10-05
DE60106974T2 (de) 2005-11-03
KR100540628B1 (ko) 2006-01-11
US6506772B1 (en) 2003-01-14
EP1347974A1 (en) 2003-10-01
AU2002231674B2 (en) 2006-07-06
UY27074A1 (es) 2002-07-31
CA2437006C (en) 2009-10-27
EP1347974B1 (en) 2004-11-03
MXPA03005334A (es) 2004-04-02
ZA200304481B (en) 2004-09-09
ES2230387T3 (es) 2005-05-01
CN1486314A (zh) 2004-03-31

Similar Documents

Publication Publication Date Title
AR031799A1 (es) Derivado de [1,2,4]triazolo[1,5-a]piridina
UY26132A1 (es) Compuestos de pirimidinona y usos para tratamiento de la arterosclerosis
EP1256574A4 (en) COMPOUNDS CONTAINING NITROGEN AND HAVING KINASE INHIBITION ACTIVITY, AND MEDICINAL PRODUCTS COMPRISING SUCH COMPOUNDS
MY117557A (en) 1-(1,2-disubstituted piperidinyl)-4- substituted piperidine derivatives
HUP0300527A2 (hu) Pirrolopirimidinon-származékok, a vegyületek előállítása és alkalmazása
MY117680A (en) 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)- piperidine derivatives
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
HUP0401711A2 (hu) TNF-alfa N-heterociklusos inhibitorai és ezeket tartalmazó gyógyszerkészítmények
HUT60733A (en) Process for producing new n-(4-piperidinyl)-(dihydrobenzofuran or dihydro-2h-benzopyran)-carboxamide derivatives and pharmaceutical compositions comprising such compounds
AR050343A1 (es) Derivados de pirimidin-urea
MY133108A (en) Muscarinic antagonists
HUP0400851A2 (hu) Dihidro-benzo[b][1,4]diazepin-2-on-származékok, mint MGluR2 II antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CO5640135A2 (es) Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer
CO5721001A2 (es) Derivados sustituidos de morfolina y tiomorfolina
MX9803407A (es) Derivados de piperazina 1-(1,2-disustituido piperidinil)-4-sustituidos.
BG103984A (en) Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
AR049699A1 (es) Derivados de pirimidina
MEP12708A (en) Derivatives of n-[phenyl (alkylpiperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
HUP0402184A2 (hu) 4-(Piperidil- és pirrolidil-alkil-ureido)-kinolin-származékok mint urotenzin II receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
UY24973A1 (es) Utilizacion de derivados de tetrahidropiridina para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan una desmielinizacion
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
SE0101579D0 (sv) New compounds
TW429256B (en) 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
PE20210417A1 (es) Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende

Legal Events

Date Code Title Description
FB Suspension of granting procedure